Benjamin J. Zeskind, PRESIDENT AND CEO at Immuneering Corp (IMRX), bought 2,400 shares at $4.56 ($11K) on 2026-06-23, disclosed to the SEC on 2026-06-24.
Immuneering CEO Benjamin J. Zeskind purchased 2,400 shares at $4.56 on June 23, 2026, marking the largest purchase of his career. This high-level endorsement comes as the stock trades near a 52-week low, suggesting confidence in the company's clinical pipeline.
The stock is down 15.4% over the past 30 days but remains up 55.1% year-to-date, trading 54.76% below its 52-week high of $10.08.
The company begins dosing in a Phase III pancreatic cancer study on June 12, 2026, and CEO Benjamin J. Zeskind made his largest-ever purchase of 2,400 shares on June 23, 2026.
The stock carries a high short interest of 25.92% of the float, and recent news noted the shares are on track for their steepest one-day decline since January 2026.
Something here stands out, but not much.
| Filing → |
| IMRX | BUY | 2024-03-19 | $55K | — | Filing → |
| IMRX | BUY | 2022-03-24 | $24K | — | Filing → |
| IMRX | BUY | 2021-09-14 | $48K | — | Filing → |